A recent study by Tayama S, et al. provided evidence that EpCAM overexpression is an independent risk factor for chemoresistance, and correlated with a lower level of cisplatin-induced apoptosis, which is regulated by EpCAM-Bcl-2 axis in ovarian cancer [23]. This evidence concerns the gene EPCAM and ovarian cancer.